These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 23929302)

  • 21. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.
    Park YJ; Song B; Kim YS; Kim EK; Lee JM; Lee GE; Kim JO; Kim YJ; Chang WS; Kang CY
    Cancer Res; 2013 Sep; 73(18):5669-81. PubMed ID: 23867469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
    Osterberg N; Ferrara N; Vacher J; Gaedicke S; Niedermann G; Weyerbrock A; Doostkam S; Schaefer HE; Plate KH; Machein MR
    Neuro Oncol; 2016 Jul; 18(7):939-49. PubMed ID: 26951383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
    Mamlouk S; Kalucka J; Singh RP; Franke K; Muschter A; Langer A; Jakob C; Gassmann M; Baretton GB; Wielockx B
    Int J Cancer; 2014 Feb; 134(4):849-58. PubMed ID: 23913502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.
    McFarland BC; Marks MP; Rowse AL; Fehling SC; Gerigk M; Qin H; Benveniste EN
    Oncotarget; 2016 Apr; 7(15):20621-35. PubMed ID: 26967393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
    Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
    J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
    Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments.
    Soldati R; Berger E; Zenclussen AC; Jorch G; Lode HN; Salatino M; Rabinovich GA; Fest S
    Int J Cancer; 2012 Sep; 131(5):1131-41. PubMed ID: 22020795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
    Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
    Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
    Hagemann C; Fuchs S; Monoranu CM; Herrmann P; Smith J; Hohmann T; Grabiec U; Kessler AF; Dehghani F; Löhr M; Ernestus RI; Vince GH; Stein U
    Neuro Oncol; 2013 Dec; 15(12):1696-709. PubMed ID: 24220141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
    Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
    Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model.
    Kim JW; Kane JR; Panek WK; Young JS; Rashidi A; Yu D; Kanojia D; Hasan T; Miska J; Gómez-Lim MA; Ulasov IV; Balyasnikova IV; Ahmed AU; Wainwright DA; Lesniak MS
    Neurotherapeutics; 2018 Oct; 15(4):1127-1138. PubMed ID: 30027430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
    Thaci B; Ahmed AU; Ulasov IV; Wainwright DA; Nigam P; Auffinger B; Tobias AL; Han Y; Zhang L; Moon KS; Lesniak MS
    Cancer Gene Ther; 2014 Jan; 21(1):38-44. PubMed ID: 24434573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
    Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
    Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
    Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
    Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses.
    Daga A; Orengo AM; Gangemi RM; Marubbi D; Perera M; Comes A; Ferrini S; Corte G
    Int J Cancer; 2007 Oct; 121(8):1756-63. PubMed ID: 17582604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparanase expression of glioma in human and animal models.
    Hong X; Nelson KK; deCarvalho AC; Kalkanis SN
    J Neurosurg; 2010 Aug; 113(2):261-9. PubMed ID: 19835469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.